BACKGROUND AND PURPOSE: Sorafenib is an inhibitor of several intracellular signalling kinases with anti-proliferative, anti-angiogenic and pro-apoptotic effects in tumour cells. Sorafenib is used in the therapy of advanced renal cell carcinoma, and several phase II clinical trials are being carried out in patients with urothelial carcinomas. EXPERIMENTAL APPROACH: Using a panel of human bladder cancer cell lines (RT4, T24, J82), we characterized systematically the effects of sorafenib on intracellular signalling, migration, proliferation and apoptosis. KEY RESULTS: We demonstrated that at low concentrations (<1 microM), sorafenib is capable of significantly stimulating migration and proliferation of the bladder cancer cells. We hypothesize that these stimulatory effects on tumour cell functions might be explained by an activation of the Ras/ERK-1/2 signal transduction pathway. In addition, the comparison of different bladder cancer cell lines not only revealed a different biology (e.g. cell migration), but also a differential susceptibility to the anti-apoptotic effects of sorafenib. Finally, we confirmed in different bladder cancer cell lines the known inhibitory actions of sorafenib in pharmacological concentrations (> or =3 microM) on ERK-1/2 phosphorylation, migration and proliferation, as well as the pro-apoptotic effects of the compound. CONCLUSIONS AND IMPLICATIONS: Taken together, these findings suggest that although sorafenib has the potential to be used in the treatment of urothelial carcinoma, this compound might also activate bladder cancer cells at low concentrations. This should be relevant for dosing regiments to optimize the treatment with this promising anti-tumour drug.
BACKGROUND AND PURPOSE:Sorafenib is an inhibitor of several intracellular signalling kinases with anti-proliferative, anti-angiogenic and pro-apoptotic effects in tumour cells. Sorafenib is used in the therapy of advanced renal cell carcinoma, and several phase II clinical trials are being carried out in patients with urothelial carcinomas. EXPERIMENTAL APPROACH: Using a panel of humanbladder cancer cell lines (RT4, T24, J82), we characterized systematically the effects of sorafenib on intracellular signalling, migration, proliferation and apoptosis. KEY RESULTS: We demonstrated that at low concentrations (<1 microM), sorafenib is capable of significantly stimulating migration and proliferation of the bladder cancer cells. We hypothesize that these stimulatory effects on tumour cell functions might be explained by an activation of the Ras/ERK-1/2 signal transduction pathway. In addition, the comparison of different bladder cancer cell lines not only revealed a different biology (e.g. cell migration), but also a differential susceptibility to the anti-apoptotic effects of sorafenib. Finally, we confirmed in different bladder cancer cell lines the known inhibitory actions of sorafenib in pharmacological concentrations (> or =3 microM) on ERK-1/2 phosphorylation, migration and proliferation, as well as the pro-apoptotic effects of the compound. CONCLUSIONS AND IMPLICATIONS: Taken together, these findings suggest that although sorafenib has the potential to be used in the treatment of urothelial carcinoma, this compound might also activate bladder cancer cells at low concentrations. This should be relevant for dosing regiments to optimize the treatment with this promising anti-tumour drug.
Authors: Scott M Wilhelm; Lila Adnane; Philippa Newell; Augusto Villanueva; Josep M Llovet; Mark Lynch Journal: Mol Cancer Ther Date: 2008-10 Impact factor: 6.261
Authors: Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J Roth; George Wilding Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Brian I Carr; Rosalba D'Alessandro; Maria G Refolo; Palma A Iacovazzi; Catia Lippolis; Caterina Messa; Aldo Cavallini; Mario Correale; Antonio Di Carlo Journal: J Cell Physiol Date: 2013-06 Impact factor: 6.384
Authors: M Danielle Bareford; Hossein A Hamed; Jeremy Allegood; Nichola Cruickshanks; Andrew Poklepovic; Margaret A Park; Besim Ogretmen; Sarah Spiegel; Steven Grant; Paul Dent Journal: Cancer Biol Ther Date: 2012-06-07 Impact factor: 4.742
Authors: Christian Niedworok; Katharina Röck; Inga Kretschmer; Till Freudenberger; Nadine Nagy; Tibor Szarvas; Frank Vom Dorp; Henning Reis; Herbert Rübben; Jens W Fischer Journal: PLoS One Date: 2013-11-06 Impact factor: 3.240